Neuroblastoma: Antibody-Based Immunotherapy

[1]  M. Imai,et al.  Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. , 2008, Cancer research.

[2]  P. Brennan,et al.  Targeting transcription factors for therapeutic benefit. , 2008, Molecular bioSystems.

[3]  T. Hughes,et al.  Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. , 2008, Cancer research.

[4]  T. Giese,et al.  Down‐regulation of CD55 and CD46 expression by anti‐sense phosphorothioate oligonucleotides (S‐ODNs) sensitizes tumour cells to complement attack , 2007, Clinical and experimental immunology.

[5]  C. Tripodo,et al.  In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. , 2007, Cancer research.

[6]  P. Heeger,et al.  Decay Accelerating Factor Can Control T Cell Differentiation into IFN-γ-Producing Effector Cells via Regulating Local C5a-Induced IL-12 Production1 , 2007, The Journal of Immunology.

[7]  Hua Yu,et al.  Activated Signal Transducers and Activators of Transcription 3 Signaling Induces CD46 Expression and Protects Human Cancer Cells from Complement-Dependent Cytotoxicity , 2007, Molecular Cancer Research.

[8]  S. Lam,et al.  Cross‐linking tumor cells with effector cells via CD55 with a bispecific mAb induces β‐glucan‐dependent CR3‐dependent cellular cytotoxicity , 2006, European journal of immunology.

[9]  T. Hughes,et al.  p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. , 2006, Cancer Research.

[10]  J. Lambris,et al.  The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo , 2005, The Journal of experimental medicine.

[11]  V. Holla,et al.  Prostaglandin E2 Regulates the Complement Inhibitor CD55/Decay-accelerating Factor in Colorectal Cancer* , 2005, Journal of Biological Chemistry.

[12]  M. Ohba,et al.  Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)- and Protein Kinase C-α/ϵ (PKCα/ϵ)-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A* , 2004, Journal of Biological Chemistry.

[13]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[14]  Z. Fishelson,et al.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. , 2003, Molecular immunology.

[15]  M. Albertini,et al.  Preclinical and clinical development of immunocytokines. , 2003, Current opinion in investigational drugs.

[16]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  A. Frankel,et al.  Effective targeted cytotoxicity of neuroblastoma cells. , 2002, Journal of pediatric surgery.

[18]  E. Erba,et al.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone , 2001, British journal of haematology.

[19]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[20]  J. Michaelis,et al.  Survival of children with neuroblastoma. time trends and regional differences in Europe, 1978--1992. , 2001, European journal of cancer.

[21]  O. Spiller,et al.  Cytokine‐mediated up‐regulation of CD55 and CD59 protects human hepatoma cells from complement attack , 2000, Clinical and experimental immunology.

[22]  N. Cheung,et al.  CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. , 2000, Cancer research.

[23]  N. Cheung,et al.  Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. , 2000, The American journal of pathology.

[24]  B. Morgan,et al.  Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59 , 1997, Clinical and experimental immunology.

[25]  J. Månsson,et al.  Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.

[26]  S. Sato,et al.  Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. , 1993, Anticancer research.

[27]  S. Gillies,et al.  Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Larson,et al.  Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  D. Munn,et al.  Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. , 1987, Cancer research.

[30]  S. Rosenberg,et al.  Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. , 1987, Journal of immunology.

[31]  K. Mujoo,et al.  Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. , 1987, Cancer research.

[32]  D. Peters,et al.  Delayed removal of renal-bound antigen in decomplemented rabbits with acute serum sickness. , 1978, Clinical and experimental immunology.

[33]  S. Gillies,et al.  Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. , 1998, Blood.

[34]  M. Schrappe,et al.  A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. , 1995, European journal of cancer.

[35]  J. Atkinson,et al.  Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function , 1989 .